title: [Additional administration of dutasteride in patients with benign prostatic hyperplasia who did not respond sufficiently to α1-adrenoceptor antagonist : investigation of clinical factors affecting the therapeutic effect of dutasteride].
abstract: We performed additional administration of dutasteride in patients who did not respond sufficiently to α1-adrenoceptor antagonist treatment for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) (LUTS/BPH). Among 76 registered patients, efficacy was analyzed in 58 patients. International Prostate Symptom Score (IPSS), subscores for voiding and storage symptoms and quality of life (QOL) on the IPSS, and Overactive Bladder Symptom Score (OABSS) were all significantly improved from the third month of administration compared to the time of initiating additional administration of dutasteride. Additional administration of dutasteride also significantly reduced prostate volume, and residual urine with the exception of the sixth month after administration. Age at initiation of administration and voiding symptom subscore on the IPSS were clinical factors affecting the therapeutic effects of dutasteride. The rate of improvement with treatment decreased with increasing age at initiation of dutasteride administration, and increased as voiding symptom subscore on the IPSS increased. Therefore, additional administration of dutasteride appears useful for cases of LUTS/BPH in which a sufficient response is not achieved with α1-adrenoceptor antagonist treatment. Because patients who have severe voiding symptoms or begin dutasteride at an early age may be expected to respond particularly well to dutasteride in terms of clinical efficacy, they were considered to be suitable targets for additional administration.
authors.affiliation: Masuda Urological Clinic.
authors.forename: Mitsunobu
authors.initials: M
authors.lastname: Masuda
authors.affiliation: International Goodwill Hospital.
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Murai
authors.affiliation: International Goodwill Hospital.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Osada
authors.affiliation: International Goodwill Hospital.
authors.forename: Masaki
authors.initials: M
authors.lastname: Kawai
authors.affiliation: Chigasaki City Hospital.
authors.forename: Jun
authors.initials: J
authors.lastname: Kasuga
authors.affiliation: Yokohama Minami Kyousai Hospital.
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Yokomizo
authors.affiliation: International Goodwill Hospital.
authors.forename: Shinnosuke
authors.initials: S
authors.lastname: Kuroda
authors.affiliation: International Goodwill Hospital.
authors.forename: Mami
authors.initials: M
authors.lastname: Nakamura
authors.affiliation: International Goodwill Hospital.
authors.forename: Go
authors.initials: G
authors.lastname: Noguchi
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage*; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000367:Age Factors; D000368:Aged; D001378:Azasteroids / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D000068538:Dutasteride; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014554:Urination; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology
chemical_list: D058891:5-alpha Reductase Inhibitors; D058668:Adrenergic alpha-1 Receptor Antagonists; D001378:Azasteroids; D000068538:Dutasteride